M&A in recent years has dramatically transformed the medtech industry, and executives have continued to sign deals, with several transactions worth hundreds of millions and the Abbott-St. Jude Medical megamerger already announced this year.

Will medtech keep up this brisk purchasing pace? Do fewer potential targets mean fewer future deals? With large medical device companies snapping up other companies, will the need for integration and time to digest those acquisitions delay or prevent other transactions?

Read on for more recent commentary from several medtech executives on their M&A outlook.

Get inspired to innovate in medtech at the MD&M East Conference, June 14-16, in New York City.